Payment overview · 2025
General Payments
$349.00
14 reported records · 7 companies
Healthcare provider profile · identity verified
Amanda Rushing-Hiser, CNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care · NORMAN, OK · NPI 1124638192
Verified facts
What the public records show
CMS Open Payments records show Amanda Rushing-Hiser, CNP received $349.00 in general payments during 2025 across 14 reported records.
Penumbra, Inc. accounted for 37.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $131.18 | 37.6% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $60.15 | 17.2% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$59.34 | 17.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.54 | 9.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.00 | 7.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.96 | 5.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.83 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $349.00 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Penumbra System Normalized: penumbra system |
Device | Penumbra, Inc. | $131.18 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $60.15 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $60.15 | 3 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $59.34 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.00 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 200 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 161 | 49 |
| Gabapentin | Gabapentin | 113 | 38 |
| Lisinopril | Lisinopril | 107 | 35 |
| Omeprazole | Omeprazole | 96 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 32 |
| Trazodone Hcl | Trazodone Hcl | 69 | 27 |
| Amlodipine Besylate | Amlodipine Besylate | 66 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 63 | 16 |
| Furosemide | Furosemide | 60 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 14 |
| Ezetimibe | Ezetimibe | 56 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 31 |
| Potassium Chloride | Potassium Chloride | 56 | 27 |
| Metformin Hcl Er | Metformin Hcl | 55 | 15 |
| Ozempic | Semaglutide | 54 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 50 | 15 |
| Metformin Hcl | Metformin Hcl | 49 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 49 | 18 |
| Prednisone | Prednisone | 49 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | suppressed |
| Meloxicam | Meloxicam | 45 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | 13 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 38 |
| Losartan Potassium | Losartan Potassium | 40 | 17 |
| Tramadol Hcl | Tramadol Hcl | 40 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 16 |
| Sertraline Hcl | Sertraline Hcl | 35 | 12 |
| Famotidine | Famotidine | 34 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 33 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | 15 |
| Alprazolam | Alprazolam | 32 | suppressed |
| Eliquis | Apixaban | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 31 | 12 |
| Simvastatin | Simvastatin | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 28 |
| Ibuprofen | Ibuprofen | 30 | 13 |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 25 |
| Glipizide | Glipizide | 28 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 24 | 12 |
| Pindolol | Pindolol | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Allopurinol | Allopurinol | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 18 |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 19 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Bethanechol Chloride | Bethanechol Chloride | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Riluzole | Riluzole | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $349.00 · 14 records | Penumbra, Inc. | ABRYSVO, COMIRNATY, Cologuard Collection Kit, ENDURANT IIS, MOUNJARO, OTEZLA, PREVNAR 20, Penumbra System, REPATHA, The Cologuard Plus Collection Kit, VOQUEZNA, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error